Bristol-Myers Squibb

LIFESPAN BIOSCIENCES, INC. SIGNS BRISTOL-MYERS SQUIBB COMPANY (BMY)
TO GPCR LOCALIZATION DATABASE

SEATTLE (February 7, 2001) — LifeSpan Biosciences, Inc., a leading genomics company using molecular pathology to profile and localize gene expression in human diseases, today announced it has entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY) for a subscription to the first database of information on the expression and localization of G protein-coupled receptors (GPCRs).  This database will provide Bristol-Myers Squibb with extremely valuable information needed for the identification and validation of new target genes for drug discovery efforts.  Bristol-Myers Squibb will receive early access to localization data on GPCR targets, which will be added continuously to the database.  Bristol-Myers Squibb will also have the opportunity to prioritize a portion of the list of GPCR genes to be included in the database based on its internal interests.  Access and updates to the database will be provided in real-time throughout the development period.  Preceded by Merck & Co., Inc., Pfizer, and the Novartis Research Foundation, Bristol-Myers Squibb is the fourth major pharmaceutical company to subscribe to LifeSpan's GPCR Database.

About LifeSpan Biosciences, Inc.

LifeSpan Biosciences, headquartered in Seattle, Washington, is a privately held genomics company founded in 1995 that utilizes proprietary molecular pathology and bioinformatics technology to profile and localize gene expression in normal and diseased human tissues for its more than 50 pharmaceutical company customers in Europe, Asia and North America.  LifeSpan is currently applying its technology and expertise to the production of a comprehensive atlas on the expression of each of the 30,000 human genes in both normal and diseased tissues.  The company's Web address is www.lsbio.com.